Dihydroberberine exhibits synergistic effects with sunitinib on NSCLC NCI‐H460 cells by repressing MAP kinase pathways and inflammatory mediators

Highly effective and attenuated dose schedules are good regimens for drug research and development. Combination chemotherapy is a good strategy in cancer therapy. We evaluated the antitumour effects of dihydroberberine combined with sunitinib (DCS) on the human non‐small cell lung cancer cell lines...

Full description

Saved in:
Bibliographic Details
Published in:J Cell Mol Med
Main Authors: Dai, Bingling, Ma, Yujiao, Wang, Wenjie, Zhan, Yingzhuan, Zhang, Dongdong, Liu, Rui, Zhang, Yanmin
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2017
Subjects:
Original Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5618684/
https://ncbi.nlm.nih.gov/pubmed/28444871
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.13178
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items